Developing anodes with a high and stable energy density for both gravimetric and volumetric storage is vital for high-performance lithium/sodium-ion batteries. Herein, an SnSe/few-layered graphene (FLG) composite with a high tap density (2.3 g cm −3 ) is synthesized via the plasma-milling method, in which SnSe nanoparticles are strongly bound with the FLG matrix, owing to both Sn−C and Se−C bonds, to form nanosized primary particles and then assemble to microsized secondary granules. The FLG can effectively alleviate the large stress generated from the volume expansion of SnSe during cycling based on its superstrength. Furthermore, as demonstrated by the density-functional theory calculations, the Sn−C and Se−C co-bonding benefitting from the formation of substantial vacancy defects on the P-milling-synthesized FLG enables strong affinity between SnSe nanoparticles and the FLG matrix, preventing SnSe from aggregating and detaching even after long-term cycling. As an anode for lithium-ion batteries, it exhibits high gravimetric and volumetric capacities (864.8 mAh g −1 and 1990 mAh cm −3 at 0.2 A g −1 ), a high rate (612.6 mAh g −1 even at 5.0 A g −1 ), and the longest life among the reported SnSe-based anodes (capacity retention of 92.8% after 2000 cycles at 1.0 A g −1 ). Subsequently, an impressive cyclic life (capacity retention of 91.6% after 1000 cycles at 1.0 A g −1 ) is also achieved for sodium-ion batteries. Therefore, the SnSe/FLG composite is a promising anode for high-performance lithium/sodium-ion batteries.
BackgroundReversible splenial lesion syndrome (RESLES) is a disorder radiologically characterized by reversible lesion in the splenium of the corpus callosum (SCC). Most of patients with RESLES associated with encephalitis/encephalopathy were identified in Japanese population, but almost no Chinese patients were diagnosed as RESLES associated with encephalitis/encephalopathy.MethodsPossible patients with reversible isolated SCC lesions were retrieved from January 2012 to July 2015 using keyword “restricted diffusion and isolated SCC lesion” in MRI report system from a large academic center. The clinical, laboratory and radiological data were summarized.ResultsA total of 15 encephalitis/encephalopathy patients (9 males and 6 females) were identified with a reversible isolated SCC lesion. Except for 13 patients with fever symptom, 8 patients also had cold symptoms before the onset of neurological symptoms. The neurological symptoms included headache, vertigo, seizure, disturbance of consciousness, and delirious behavior. Thirteen patients completely recovered within 1 month, but 2 patients who were subjected to mechanical ventilation had persistent neurological deficits. The initial MRI features showed isolated ovoid or extending SCC lesions with homogeneous hyperintense on diffusion weighted imaging (DWI) and decreased apparent diffusion coefficient (ADC) values. The follow-up MRI revealed that isolated SCC lesions with diffuse restriction disappeared at 10 to 32 days after the initial MRI study. Fractional anisotropy map revealed the decreased value of SCC lesion in a severe case with poor prognosis.ConclusionsRESLES associated with encephalitis/encephalopathy is a reversible syndrome with an excellent prognosis in most patients, while a few patients required ventilator supporting at the early stage might have severe neurological sequelae. Reversible signal changes on DWI and ADC are identified in all patients, but fractional anisotropy values can be decreased in severe patient with neurological sequelae.Electronic supplementary materialThe online version of this article (doi:10.1186/s12883-016-0572-9) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.